Format

Send to

Choose Destination
Eur J Hybrid Imaging. 2018;2(1):17. doi: 10.1186/s41824-018-0035-1. Epub 2018 Aug 22.

Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population.

Author information

1
1Department of Nuclear Medicine and Specialised PET Service, Ned Hanlon Building, Royal Brisbane and Women's Hospital (RBWH), Herston, QLD 4029 Australia.
2
2School of Medicine, James Cook University, Douglas, QLD 4811 Australia.
3
3Department of Cardiology RBWH, Herston, QLD 4029 Australia.
4
4School of Clinical Medicine, Faculty of Medicine, University of Queensland, Heston, QLD 4006 Australia.

Abstract

Background:

99mTechnetium-HDP (HDP) bone scans differentiate transthyretin (ATTR) cardiac amyloid from other infiltrative myocardial diseases. These scans are not quantitative and are assessed by comparing myocardial uptake to bone. This study examined whether quantitative HDP SPECT/CT can discriminate individuals with cardiac ATTR from the population without this disease.

Methods:

HDP thoracic xSPECT/CT QUANT (xQUANT) was performed in 29 patients: ATTR cardiac amyloid (n = 6); AL cardiac amyloid (n = 1); other infiltrative myocardial disease (n = 4); no known infiltrative cardiac disease (n = 18). SUVmax measured within volumes of interest for whole heart, ascending aorta blood pool, and specific bones. HDP myocardial uptake calculated as whole heart minus blood pool.

Results:

The cardiac ATTR group had greater HDP myocardial uptake than those with no known infiltrative disease (p = 0.002). AL and other myocardial diseases had uptake indistinguishable from the group with no known infiltrative cardiac disease. The SUVmaxima were sufficiently similar between individuals without cardiac ATTR that a 99% reference interval for HDP uptake could be calculated, providing an upper limit cut point of SUVmax 1.2. Individuals with cardiac ATTR had SUVmax well above this cut point.

Conclusion:

Quantitative SPECT/CT can measure HDP myocardial uptake in individuals with normal hearts and those with cardiac ATTR without recourse to comparison with bone. It enables calculation of a reference interval for HDP myocardial uptake in the population without ATTR cardiac amyloid. Using this reference interval single individuals with cardiac ATTR can be accurately discriminated from the non-affected population. This technique uses a NIST traceable calibration source, potentially allowing development of multicentre clinical decision limits. Its role in disease management warrants further assessment.

KEYWORDS:

ATTR; Cardiac amyloid; Quantitative SPECT; Tc-HDP

Conflict of interest statement

The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center